Highlights Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.04 ^USD	+5.70%		-1.45%	-38.74%

Apr. 24	Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting	CI
Mar. 20	HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting	Apr. 24	CI
Coherus BioSciences Shares Fall After Workforce Reduction Plan; Q4 Loss	Mar. 14	MT
Earnings Flash (CHRS) COHERUS BIOSCIENCES Reports Q4 Revenue $91.5M, vs. Street Est of $90.4M	Mar. 13	MT
Coherus BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 13	CI
Coherus BioSciences Completes $170 Million Sale of Ophthalmology Franchise to Sandoz	Mar. 04	MT
Sandoz: acquisition of Cimerli finalized	Mar. 04	CF
Sandoz Inc. completed the acquisition of CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc..	Feb. 29	CI
Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv	Feb. 21	CI
KKR to acquire a stake in health tech firm Cotiviti	Feb. 14	RE
BioPharma Credit to receive partial prepayment of loan	Feb. 06	AN
Correction: Coherus BioSciences to Sell Cimerli Ophthalmology Business to Sandoz for $170 Million	Jan. 22	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday on Bets of Strong Mega-Cap Earnings	Jan. 22	MT
Coherus BioSciences to Sell Cemerli Ophthalmology Business to Sandoz for $170 Million	Jan. 22	MT
Sandoz: acquisition of ophthalmology biosimilar	Jan. 22	CF
Sandoz to Acquire Cimerli Business from Coherus for $170 Million	Jan. 22	DJ
Sandoz to Buy Lucentis Biosimilar in US for $170 Million	Jan. 22	MT
Sandoz to buy eye drug Cimerli in $170 million deal	Jan. 22	RE
Sandoz Group AG entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. for approximately $170 million.	Jan. 21	CI
Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium	Jan. 18	CI
Inovio Pharmaceuticals, Coherus BioSciences to Collaborate on Potential Throat Cancer Treatment	Jan. 04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Coherus BioSciences, Inc.

Equities

CHRS

US19249H1032

Highlights

Filters